Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

Neurobiology of Disease

Volumn 15, Issue 2, 2004, Pages 171-176

  Tahar, Abdallah Hadj ^a   Grégoire, Laurent ^a   Darré, Aurélie ^a   Bélanger, Nancy ^a   Meltzer, Leonard ^b   Bédard, Paul J ^a  

^a LAVAL UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

Author keywords

CI 1041; L dopa induced dyskinesias; MPTP monkeys; NMDA receptor; Parkinson's disease; Prevention

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CI 1041; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; DYSKINESIA; FEMALE; LOCOMOTION; MONKEY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; BENZOXAZOLES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLUTAMIC ACID; LEVODOPA; MACACA FASCICULARIS; PARKINSON DISEASE; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 1542360582     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.10.007     Document Type: Article

References (42)

1. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.S. IV, Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48.
2. Bédard P.J., Blanchet P.J., Lévesque D., Soghomonian J.J., Grondin R., Morissette M., Goulet M., Calon F., Falardeau P., Gomez-Mancilla B., Doucet J.P., Robertson G.S., DiPaolo T. Pathophysiology of L-dopa-induced dyskinesias. Mov. Disord. 14:1999;4-8.
3. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13:1998;798-802.
4. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290:1999;1034-1040.
5. Calabresi P., Giacomini P., Centonze D., Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol. 47:2000;S60-S68.
6. Calon F., Hadj Tahar A., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., Bédard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23:2000;S92-S100.
7. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bédard P.J., Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 26:2002;127-138.
8. Centonze D., Calabresi P., Giacomini P., Bernardi G. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin. Neurophysiol. 110:1999;2006-2013.
9. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Natl. Acad. Sci. U. S. A. 90:1993;9576-9580.
10. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 10:2000;S86-S91.
11. Chen L.R., Wesley J.A., Bhattachar S., Ruiz B., Bahash K., Babu S.R. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm. Res. 20(5):2003;797-801. (May).
12. Christoffersen C.L., Wright J.L., Kesten S.R., Meltzer L.T. Effects of CI-1041, a selective NMDA 1A/2B receptor antagonist, in MPTP treated monkeys. Soc. Neurosci. 2000;1409. (Abstr. #528.8).
13. Coughenour L.L., Barr B., Espitia S.et al. Neurochemical pharmacology of CI-1041 (PD 196860): a novel subtype selective NMDA antagonist. Soc. Neurosci. 2000;1406. (Abstr., #527.4.).
14. Difazio M.C., Hollingsworth Z., Young A.B., Penney J.B. Jr. Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology. 42:1992;402-406.
15. Di Paolo T., Bédard P., Daigle M., Boucher R. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain Res. 379:1986;286-293.
16. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57:2000;342-352.
17. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S2-S9.
18. Ferreira J.J., Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr. Opin. Neurol. 13:2000;431-436.
19. Hadj Tahar A., Grégoire L., Bangassoro E., Bédard P.J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin. Neuropharmacol. 23:2000;195-202.
20. He L., Di Monte D.A., Langston J.W., Quik M. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment. Neuroscience. 99:2000;697-704.
21. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342.
22. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
23. Meldrum B.S. The glutamate synapse as a therapeutical target: perspectives for the future. Prog. Brain Res. 116:1998;441-458.
24. Montastruc J.L., Rascol O., Senard J.M. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov. Disord. 14:1999;725-730.
25. Mutel V., Buchy D., Klingelschmidt A., Messer J., Bleuel Z., Kemp J.A., Richards J.G. In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. 70:1998;2147-2155.
26. Nagy J., Kolok S., Dezso P., Boros A., Szombathelyi Z. Differential alterations in the expression of NMDA receptor subunits following chronic ethanol treatment in primary cultures of rat cortical and hippocampal neurones. Neurochem. Int. 42(1):2003;35-43. (Jan).
27. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165:2000;136-142.
28. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23:2000;S8-S19.
29. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
30. Ravenscroft P., Brotchie J. Alterations in striatal NR1 and NR2B NMDA receptor subunit expression in the 6-OHDA-lesioned rat model of L-dopa-induced dyskinesia. (Abstract) Parkinsonism Relat. Disord. 5:1999;S42. (Suppl).
31. Ravenscroft P., Brotchie J. NMDA receptors in the basal ganglia. J. Anat. 196:2000;577-585.
32. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44:1998;S175-S188.
33. Serpa K.A., Wright J.L., Kesten S.R., Meltzer L.T. Antiparkinsonian (AP) effects of CI-1041 (PD196860), a subtype selective NMDA antagonist, in the 6-OHDA rat model. Soc. Neurosci. 2000;1409. (Abstr., #528.7).
34. Snow B.J., Vingerhoets F.J., Langston J.W., Tetrud J.W., Sossi V., Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry. 68:2000;313-316.
35. Standaert D.G., Testa C.M., Young A.B., Penney J.B. Jr. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343:1994;1-16.
36. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. 163:2000;239-243.
37. Suen P.C., Wu K., Xu J.L., Lin S.Y., Levine E.S., Black I.B. NMDA receptor subunits in the postsynaptic density of rat brain: expression and phosphorylation by endogenous protein kinases. Brain Res. Mol. Brain Res. 59:1998;215-228.
38. Tanner C.M., Aston D.A. Epidemiology of Parkinson's disease and akinetic syndromes. Curr. Opin. Neurol. 13:2000;427-430.
39. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J. Neurosci. 14:1994;6317-6324.
40. Verhagen Metman L., Blanchet P.J., van den Munckhof P., Del Dotto P., Natte R., Chase T.N. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov. Disord. 13:1998;414-417.
41. Weiner W.J. The initial treatment of Parkinson's disease should begin with levodopa. Mov. Disord. 14:1999;716-724.
42. Whittemore E.R., Ilyin V.I., Woodward R.M. Electrophysiological characterization of CI-1041 on cloned and native NMDA receptors. Soc. Neurosci. 2000;1406. (Abstr., #527.3).